Year: 2015
Type: article
Study design: Observational Study
Abstract: BACKGROUND: To establish whether Parkinson's disease (PD) brains previously described to have decreased glucocerebrosidase activity exhibit accumulation of the lysosomal enzyme's substrate, glucosylceramide, or other changes in lipid composition. METHODS: Lipidomic analyses and cholesterol measurements were performed on the putamen (n = 5-7) and cerebellum (n = 7-14) of controls, Parkinson's disease brains with heterozygote GBA1 mutations (PD+GBA), or sporadic PD. RESULTS: Total glucosylceramide levels were unchanged in both PD+GBA and sporadic PD brains when compared with controls. No changes in glucosylsphingosine (deacetylated glucosylceramide), sphingomyelin, gangliosides (GM2, GM3), or total cholesterol were observed in either putamen or cerebellum. CONCLUSIONS: This study did not demonstrate glucocerebrosidase substrate accumulation in PD brains with heterozygote GBA1 mutations in areas of the brain with low α-synuclein pathology.
Source: Movement Disorders
DOI: 10.1002/mds.26278
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,181
Awards: G2513708871, G2845388095, A systematic investigation into the pathogenesis and course of Parkinson's syndrome, Targeting glucocerebrosidase for disease-modifying treatments in Parkinson's disease, NIHR Senior Investigator Award, A systematic investigation into the pathogenesis and course of Parkinson's syndrome.
OpenAlex ID: W1558432922
